Thereby, one could imagine that lysosomal-targeted treatment options developed for PDGBA (Mullin et al., 2020) might be also beneficial for other PD subgroups in which lysosomal dysfunction driving alpha-synuclein accumulation plays a major role. This evidence concerns the gene SNCA and Parkinson disease.